ARCH Venture Fund VIII Overage, L.P.'s Net Worth
$525 Million
Who is ARCH Venture Fund VIII Overage, L.P.?
ARCH Venture Fund VIII Overage, L.P. has an estimated net worth of $525 Million. This is based on reported shares across multiple companies, which include Neumora Therapeutics, Inc., Quanterix Corp, Twist Bioscience Corp, Metacrine, Inc., Unity Biotechnology, Inc., Codiak BioSciences, Inc., Sienna Biopharmaceuticals, Inc., and Homology Medicines, Inc..
SEC CIK
ARCH Venture Fund VIII Overage, L.P.'s CIK is 0001617237
Past Insider Trading and Trends
2020 was ARCH Venture Fund VIII Overage, L.P.'s most active year for acquiring shares with 16 total transactions. ARCH Venture Fund VIII Overage, L.P.'s most active month to acquire stocks was the month of August. 2020 was ARCH Venture Fund VIII Overage, L.P.'s most active year for disposing of shares, totalling 13 transactions. ARCH Venture Fund VIII Overage, L.P.'s most active month to dispose stocks was the month of August. 2023 saw ARCH Venture Fund VIII Overage, L.P. paying a total of $25,500,000.00 for 18,924,704 shares, this is the most they've acquired in one year. In 2020 ARCH Venture Fund VIII Overage, L.P. cashed out on 30,643,367 shares for a total of $0.00, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Metacrine, Inc. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
|
∞
| 2.94M |
$13.00 |
—
| 2.94M |
Sep 18
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
Unity Biotechnology, Inc. (UBX) Snapshot price: $1.7389
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
| +25,308.20% | 10.01M |
—
|
—
| 10.05M |
May 7
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
Codiak BioSciences, Inc. (CDAKQ) No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
| +129.73% | 5M |
$1.50 | $7,500,000.00 | 8.85M |
Sep 13
| |||
Form 4
| +75.61% | 3.79M |
$15.00 | $3,525,000.00 | 8.8M |
Oct 16
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
Sienna Biopharmaceuticals, Inc. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
| +59.61% | 2.17M |
$2.50 | $5,414,500.00 | 5.8M |
Feb 22
| |||
Form 4
|
∞
| 3.63M |
—
|
—
| 3.63M |
Aug 1
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
Homology Medicines, Inc. (FIXX) Snapshot price: $0.715
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
| -4.94% | -300.00K |
—
|
—
| 5.77M |
May 21
| |||
Form 4
|
∞
| 6.07M |
—
|
—
| 6.07M |
Apr 2
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |